BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
China's GLP-1 landscape
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
PFA re-energizes afib market
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Sunday, October 6, 2024
See today's BioWorld
Home
» Minerva renews its drive to an NDA in treating schizophrenia
To read the full story,
subscribe
or
sign in
.
Minerva renews its drive to an NDA in treating schizophrenia
May 12, 2021
By
Lee Landenberger
No Comments
Bolstered by new and positive open-label extension data, Minerva Neurosciences Inc. won’t let a failed phase III of roluperidone in treating schizophrenia get in the way of considering an NDA filing.
BioWorld
Clinical
Neurology/psychiatric